{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:45:34Z","timestamp":1781649934648,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Proton pump inhibitors (PPIs) are widely used for the treatment of gastrointestinal disorders such as peptic ulcer disease and dyspepsia. However, several studies have suggested that PPI use increases the risk of acute kidney injury (AKI). PPIs are often concomitantly used with antibiotics, such as macrolides and penicillins for <jats:italic>Helicobacter pylori<\/jats:italic> eradication. Although macrolide antibiotics are considered to have relatively low nephrotoxicity, they are well known to increase the risk of AKI due to drug-drug interactions. In this study, we aimed to investigate the association between PPI use and the development of AKI. We also evaluated the effect of concomitant use of PPIs and macrolide antibiotics on the risk of AKI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This self-controlled case series study was conducted using electronic medical records at Kyoto University Hospital. We identified patients who were prescribed at least one PPI and macrolide antibiotic between January 2014 and December 2019 and underwent blood examinations at least once a year. An adjusted incident rate ratio (aIRR) of AKI with PPI use or concomitant use macrolide antibiotics with PPIs was estimated using a conditional Poisson regression model controlled for the estimated glomerular filtration rate at the beginning of observation and use of potentially nephrotoxic antibiotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 3,685 individuals who received PPIs and macrolide antibiotics, 766 patients with episodes of stage 1 or higher AKI were identified. Any stage of AKI was associated with PPI use (aIRR, 1.80 (95% confidence interval (CI) 1.60 to 2.04)). Stage 2 or higher AKI was observed in 279 cases, with an estimated aIRR of 2.01 (95% CI 1.57 to 2.58, for PPI use). For the period of concomitant use of macrolide antibiotics with PPIs compared with the period of PPIs alone, an aIRR of stage 1 or higher AKI was estimated as 0.82 (95% CI 0.60 to 1.13).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings added epidemiological information for the association between PPI use and an increased risk of stage 1 or higher AKI. However, we did not detect an association between the concomitant use of macrolide antibiotics and an increased risk of AKI in PPI users.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-03008-x","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:04:50Z","timestamp":1669795490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of proton pump inhibitors and macrolide antibiotics and risk of acute kidney injury: a self-controlled case series study"],"prefix":"10.1186","volume":"23","author":[{"given":"Keiko","family":"Ikuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinami","family":"Yamawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Itohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Sakuragi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,30]]},"reference":[{"issue":"2","key":"3008_CR1","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.9778\/cmajo.20140074","volume":"3","author":"T Antoniou","year":"2015","unstructured":"Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166\u201371.","journal-title":"CMAJ Open"},{"key":"3008_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2369-14-150","volume":"14","author":"DG Klepser","year":"2013","unstructured":"Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150.","journal-title":"BMC Nephrol"},{"issue":"4","key":"3008_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ki.2014.74","volume":"86","author":"ML Blank","year":"2014","unstructured":"Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837\u201344.","journal-title":"Kidney Int"},{"issue":"4","key":"3008_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/phar.2235","volume":"39","author":"E Hart","year":"2019","unstructured":"Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019;39(4):443\u201353.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"3008_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238\u201346.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"3008_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","volume":"153","author":"DCF Klatte","year":"2017","unstructured":"Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702\u201310.","journal-title":"Gastroenterology"},{"issue":"6","key":"3008_CR7","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482\u201394.","journal-title":"Kidney Int"},{"issue":"10","key":"3008_CR8","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"3008_CR9","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/jcph.805","volume":"56","author":"J Lee","year":"2016","unstructured":"Lee J, Mark RG, Celi LA, Danziger J. Proton pump inhibitors are not associated with acute kidney injury in critical illness. J Clin Pharmacol. 2016;56(12):1500\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"21","key":"3008_CR10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.21037\/atm-20-2284","volume":"8","author":"Y Li","year":"2020","unstructured":"Li Y, Xiong M, Yang M, Wang L, Nie S, Liu D, et al. Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children. Ann Transl Med. 2020;8(21):1438.","journal-title":"Ann Transl Med"},{"issue":"7","key":"3008_CR11","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1111\/bcp.14713","volume":"87","author":"S Liabeuf","year":"2021","unstructured":"Liabeuf S, Lambert O, Metzger M, Hamroun A, Laville M, Laville SM, et al. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: the CKD-REIN cohort study. Br J Clin Pharmacol. 2021;87(7):2967\u201376.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"3008_CR12","doi-asserted-by":"publisher","first-page":"e041543","DOI":"10.1136\/bmjopen-2020-041543","volume":"11","author":"K Ikuta","year":"2021","unstructured":"Ikuta K, Nakagawa S, Momo K, Yonezawa A, Itohara K, Sato Y, et al. Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study. BMJ Open. 2021;11(2):e041543.","journal-title":"BMJ Open"},{"issue":"6","key":"3008_CR13","doi-asserted-by":"publisher","first-page":"e001821","DOI":"10.1136\/bmjopen-2012-001821","volume":"2","author":"YJ Hwang","year":"2012","unstructured":"Hwang YJ, Shariff SZ, Gandhi S, Wald R, Clark E, Fleet JL, et al. Validity of the international classification of diseases, tenth revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission. BMJ Open. 2012;2(6):e001821.","journal-title":"BMJ Open"},{"issue":"11","key":"3008_CR14","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1002\/phar.1660","volume":"35","author":"AE Woodruff","year":"2015","unstructured":"Woodruff AE, Meaney CJ, Hansen EA, Prescott GM. Azithromycin-induced, biopsy-proven acute interstitial nephritis in an adult successfully treated with low-dose corticosteroids. Pharmacotherapy. 2015;35(11):e169\u201374.","journal-title":"Pharmacotherapy"},{"issue":"23","key":"3008_CR15","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2013.282426","volume":"310","author":"S Gandhi","year":"2013","unstructured":"Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544\u201353.","journal-title":"JAMA"},{"issue":"3","key":"3008_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1503\/cmaj.140950","volume":"187","author":"DQ Li","year":"2015","unstructured":"Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. CMAJ. 2015;187(3):174\u201380.","journal-title":"CMAJ"},{"issue":"3","key":"3008_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0009-9236(99)70034-2","volume":"66","author":"T Furuta","year":"1999","unstructured":"Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther. 1999;66(3):265\u201374.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3008_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/chir.20159","volume":"17","author":"M Miura","year":"2005","unstructured":"Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, et al. Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. Chirality. 2005;17(6):338\u201344.","journal-title":"Chirality"},{"issue":"3","key":"3008_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.5414\/CPP44119","volume":"44","author":"M Hassan-Alin","year":"2006","unstructured":"Hassan-Alin M, Andersson T, Niazi M, Liljeblad M, Persson BA, R\u00f6hss K. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects. Int J Clin Pharmacol Ther. 2006;44(3):119\u201327.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"3008_CR20","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/sim.2302","volume":"25","author":"HJ Whitaker","year":"2006","unstructured":"Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768\u201397.","journal-title":"Stat Med"},{"key":"3008_CR21","doi-asserted-by":"publisher","first-page":"i4515","DOI":"10.1136\/bmj.i4515","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515.","journal-title":"BMJ"},{"key":"3008_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/CLEP.S158110","volume":"10","author":"S Hiragi","year":"2018","unstructured":"Hiragi S, Yamada H, Tsukamoto T, Yoshida K, Kondo N, Matsubara T, et al. Acetaminophen administration and the risk of acute kidney injury: a self-controlled case series study. Clin Epidemiol. 2018;10:265\u201376.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"3008_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000439146","volume":"131","author":"NM Selby","year":"2015","unstructured":"Selby NM, Hill R, Fluck RJ. Standardizing the early identification of acute kidney injury: the NHS England National Patient Safety Alert. Nephron. 2015;131(2):113\u20137.","journal-title":"Nephron"},{"key":"3008_CR24","doi-asserted-by":"publisher","first-page":"106129","DOI":"10.1016\/j.cmpb.2021.106129","volume":"206","author":"N Sato","year":"2021","unstructured":"Sato N, Uchino E, Kojima R, Hiragi S, Yanagita M, Okuno Y. Prediction and visualization of acute kidney injury in intensive care unit using one-dimensional convolutional neural networks based on routinely collected data. Comput Methods Prog Biomed. 2021;206:106129.","journal-title":"Comput Methods Prog Biomed"},{"issue":"12","key":"3008_CR25","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/ndt\/gfs375","volume":"27","author":"D Fliser","year":"2012","unstructured":"Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, et al. A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263\u201372.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"3008_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","volume":"6","author":"B Isik","year":"2021","unstructured":"Isik B, Alexander MP, Manohar S, Vaughan L, Kottschade L, Markovic S, et al. Biomarkers, clinical features, and Rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney Int Rep. 2021;6(4):1022\u201331.","journal-title":"Kidney Int Rep"},{"key":"3008_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/CLEP.S146757","volume":"10","author":"KE Mansfield","year":"2018","unstructured":"Mansfield KE, Douglas IJ, Nitsch D, Thomas SL, Smeeth L, Tomlinson LA. Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis. Clin Epidemiol. 2018;10:187\u2013202.","journal-title":"Clin Epidemiol"},{"issue":"4","key":"3008_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2015.02.337","volume":"66","author":"ME Grams","year":"2015","unstructured":"Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, et al. A Meta-analysis of the Association of Estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis. 2015;66(4):591\u2013601.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3008_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1681\/ASN.2009060636","volume":"21","author":"JP Lafrance","year":"2010","unstructured":"Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21(2):345\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3008_CR30","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1681\/ASN.2004090740","volume":"16","author":"GM Chertow","year":"2005","unstructured":"Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16(11):3365\u201370.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3008_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2125.2010.03623.x","volume":"69","author":"NA Helsby","year":"2010","unstructured":"Helsby NA, Lo WY, Simpson IJ, Voss DM, Logan KE, Searle M, et al. Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br J Clin Pharmacol. 2010;69(5):516\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3008_CR32","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/pds.3329","volume":"21","author":"CE Leonard","year":"2012","unstructured":"Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, et al. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. 2012;21(11):1155\u201372.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"3008_CR33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2036.2007.03407.x","volume":"26","author":"F Sierra","year":"2007","unstructured":"Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545\u201353.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3008_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1053\/j.ackd.2016.11.004","volume":"24","author":"R Raghavan","year":"2017","unstructured":"Raghavan R, Shawar S. Mechanisms of drug-induced interstitial nephritis. Adv Chronic Kidney Dis. 2017;24(2):64\u201371.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"3008_CR35","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","volume":"69","author":"RK Weersma","year":"2020","unstructured":"Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510\u20139.","journal-title":"Gut"},{"issue":"1","key":"3008_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41467-017-00796-x","volume":"8","author":"C Llorente","year":"2017","unstructured":"Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017;8(1):837.","journal-title":"Nat Commun"},{"issue":"6","key":"3008_CR37","doi-asserted-by":"publisher","first-page":"e0131909","DOI":"10.1371\/journal.pone.0131909","volume":"10","author":"S Sawhney","year":"2015","unstructured":"Sawhney S, Marks A, Ali T, Clark L, Fluck N, Prescott GJ, et al. Maximising Acute Kidney Injury Alerts--A Cross-Sectional Comparison with the Clinical Diagnosis. PLoS One. 2015;10(6):e0131909.","journal-title":"PLoS One"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03008-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-03008-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-03008-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T08:08:52Z","timestamp":1669795732000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-03008-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3008"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-03008-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine on April 26,2021 (R2957). The need for Informed Consent was waived by the same ethics committee (Ethics Committee of Kyoto University Graduate School and Faculty of Medicine) that approved the study due to the retrospective nature of the study. However, general information about the study was provided on hospital bulletin boards and website. It was stated that if potential participants offered to refuse enrolment in the study, they would not be included in the study. No one offered to refuse to be included in the study. All experiments were performed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and Declaration of Helsinki guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests<b>.<\/b>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"383"}}